Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma

Neuro-Oncology

Volumn 19, Issue 7, 2017, Pages 965-975

  Reardon, David A ^a   Lassman, Andrew B ^b   Van Den Bent, Martin ^c   Kumthekar, Priya ^d   Merrell, Ryan ^e   Scott, Andrew M ^f,g   Fichtel, Lisa ^h   Sulman, Erik P ⁱ   Gomez, Erica ^j   Fischer, Judee ^j   Lee, Ho Jin ^j   Munasinghe, Wijith ^j   Xiong, Hao ^j   Mandich, Helen ^j   Roberts Rapp, Lisa ^j   Ansell, Peter ^j   Holen, Kyle D ^j   Gan, Hui K ^f,g,k  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b Department of Medicine   (United States)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d NORTHWESTERN UNIVERSITY   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^g LA TROBE UNIVERSITY   (Australia)

^h South Texas Accelerated Research Therapeutics (START)   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j ABBVIE INC   (United States)

^k UNIVERSITY OF MELBOURNE   (Australia)

more..

Author keywords

ABT 414; antibody drug conjugate; EGFR; glioblastoma; phase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DEPATUXIZUMAB MAFODOTIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ABT-414; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; DACARBAZINE; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLURRED VISION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; EYE PAIN; EYE TOXICITY; FATIGUE; FEMALE; GENE; GENE MUTATION; GLIOBLASTOMA; HUMAN; IDH1 GENE; KERATITIS; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MGMT GENE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOTOPHOBIA; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SEIZURE; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; ANALOGS AND DERIVATIVES; BRAIN TUMOR; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOCONJUGATES; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85021693939     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/now257     Document Type: Article

References (50)

1. Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17 Suppl 4:iv1-iv62.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
3. Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumortreating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535-2543.
4. Wick W, Brandes AA, Gorlia T, et al. Phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the EORTC 26101 trial. Neuro Oncol. 2015;17 (suppl 5): v1.
5. Brennan CW, Verhaak RG, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462-477.
6. Yoshimoto K, Dang J, Zhu S, et al. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008;14(2):488-493.
7. Gan HK, Cvrljevic AN, Johns TG. The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013;280(21):5350-5370.
8. Chen JR, Xu HZ, Yao Y, et al. Prognostic value of epidermal growth factor receptor amplification and EGFRvIII in glioblastoma: meta-analysis. Acta Neurol Scand. 2015;132(5):310-322.
9. Weller M, Kaulich K, Hentschel B, et al. Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy. Int J Cancer. 2014;134(10):2437-2447.
10. Zhao LL, Xu KL, Wang SW, et al. Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas. Histopathology. 2012;61(4):726-736.
11. Montano N, Cenci T, Martini M, et al. Expression of EGFRvIII in glioblastoma: prognostic significance revisited. Neoplasia. 2011;13(12):1113-IN1116.
12. Chakravarti A, Wang M, Robins HI, et al. RTOG 0211: a phase study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys. 2013;85(5):1206-1211.
13. Uhm JH, Ballman KV, Wu W, et al. Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys. 2011;80(2):347-353.
14. Peereboom DM, Shepard DR, Ahluwalia MS, et al. Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol. 2010;98(1):93-99.
15. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
16. Neyns B, Sadones J, Joosens E, et al. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma. Ann Oncol. 2009;20(9):1596-1603.
17. Raizer JJ. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol. 2005;74(1):77-86.
18. Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;15(4):661-669.
19. Scott AM, Lee FT, Tebbutt N, et al. A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A. 2007;104(10):4071-4076.
20. Jungbluth AA, Stockert E, Huang HJ, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci U S A. 2003;100(2):639-644.
21. Gan HK, Burgess AW, Clayton AH, et al. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012;72(12):2924-2930.
22. Gan HK, Burge ME, Solomon BJ, et al. A phase I and biodistribution study of ABT-806i, an 111indium-labeled conjugate of the tumor-specific anti-EGFR antibody ABT-806. J Clin Oncol. 2013;31(suppl; abstr 2520).
23. Gan HK, Fichtel L, Lassman A, et al. A Phase I study evaluating ABT-414 with concurrent radiotherapy (RT) and temozolomide (TMZ) in glioblastoma (GBM). Presented at Society for Neuro-Oncology, November 13-16, 2014;Miami, Florida. 2014.
24. Gan HK, Fichtel L, Lassman AB, et al. A phase I study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). J Clin Oncol. 2014;32:5s (suppl; abstr 2021).
25. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997-1003.
26. Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas. Clin Cancer Res. 2009;15(19):6002-6007.
27. Crespo I, Vital AL, Gonzalez-Tablas M, et al. Molecular and genomic alterations in glioblastoma multiforme. Am J Pathol. 2015;185(7):1820-1833.
28. Li J, Wang M, Won M, et al. Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys. 2011;81(3):623-630.
29. Curran WJ Jr, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85(9):704-710.
30. Chakravarti A, Wang M, Aldape KD, et al. A revised RTOG recursive partitioning analysis (RPA) model for glioblastoma based upon multiplatform biomarker profiles. J Clin Oncol. 2012;30(suppl; abstr 2001).
31. Aldape KD, Wang M, Sulman EP, et al. RTOG 0525: Molecular correlates from a randomized phase III trial of newly diagnosed glioblastoma. J Clin Oncol 2011;29 (suppl; abstr LBA2000).
32. Qi X, Munasinghe W, Hosmane B, et al. Exposure Adjusted Continuous Reassessment Method (EACRM)-an adaptive design incorporating time to toxicity event for phase I dose finding studies. Drug Designing. 2015;4(2):122.
33. Michael M, Mulcahy MF, Deming DA, et al. Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer (LARC): final results of a phase Ib study. J Clin Oncol. 2015;33(suppl; abstr 3571).
34. Gan HK, Papadopoulos KP, Fichtel L, et al. Phase I study of ABT-414 mono-or combination therapy with temozolomide (TMZ) in recurrent glioblastoma (GBM). J Clin Oncol. 2015;33 (suppl; abstr 2016). 2015.
35. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol. 2010;28(11):1963-1972.
36. Han TH, Gopal AK, Ramchandren R, et al. CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibodydrug conjugate, in patients with CD30-positive hematologic malignancies. J Clin Pharmacol. 2013;53(8):866-877.
37. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60(9):2368-2371.
38. Vlassenbroeck I, Califice S, Diserens AC, et al. Validation of realtime methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn. 2008;10(4):332-337.
39. Younes A, Yasothan U, Kirkpatrick P. Brentuximab vedotin. Nat Rev Drug Discov. 2012;11(1):19-20.
40. Peddi PF, Hurvitz SA. Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential. Ther Adv Med Oncol. 2014;6(5):202-209.
41. Tannir NM, Forero-Torres A, Ramchandren R, et al. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. 2014;32(6):1246-1257.
42. Thompson JA, Motzer R, Molina AM, et al. Phase I studies of anti-ENPP3 antibody drug conjugates (ADCs) in advanced refractory renal cell carcinomas (RRCC). J Clin Oncol 2015;33 (suppl; abstr 2503).
43. Lochhead J, Salmon JF, Bron AJ. Cytarabine-induced corneal toxicity. Eye (Lond). 2003;17(5):677-678.
44. Hopen G, Mondino BJ, Johnson BL, Chervenick PA. Corneal toxicity with systemic cytarabine. Am J Ophthalmol. 1981;91(4):500-504.
45. Matteucci P, Carlo-Stella C, Di Nicola M, et al. Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside. Haematologica. 2006;91(2):255-257.
46. Cytarabine package insert, APP pharmaceuticals
47. Goss GD, Vokes EE, Gordon MS, et al. ABT-414 in patients with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). J Clin Oncol 33, 2015 (suppl; abstr 2510). 2015.
48. Brentuximab vedotin, Adcetris package insert, Seattle Genetics.
49. Schmidt-Ullrich RK, Mikkelsen RB, Dent P, et al. Radiationinduced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene. 1997;15(10):1191-1197.
50. Cao Y, Tsien CI, Shen Z, et al. Use of magnetic resonance imaging to assess blood-brain/blood-glioma barrier opening during conformal radiotherapy. J Clin Oncol. 2005;23(18):4127-4136.